Test to Classify Metastasis Risk in Prostate Cancers Validated by Study, GenomeDx Reports

Test to Classify Metastasis Risk in Prostate Cancers Validated by Study, GenomeDx Reports
GenomeDx Biosciences has announced the publication of a validation study of its Decipher Prostate Cancer Classifier, a genomic test for prostate cancer (PC) designed to improve clinical decisions regarding patient treatment and risk of metastasis following a diagnostic biopsy or radical prostatectomy (RP). The study “Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk,” was published in the

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *